Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings  by Ford, Nathan et al.
T
re
a
tm
e
n
t
Journal of Hepatology Update: Hepatitis CSimpliﬁcation of antiviral hepatitis C virus therapy to
support expanded access in resource-limited settings
Nathan Ford1, Tracy Swan2, Peter Beyer3, Gottfried Hirnschall1, Philippa Easterbrook1,
Stefan Wiktor1,⇑
1Department of HIV/AIDS, World Health Organization, Geneva, Switzerland; 2Treatment Action Group, New York, USA; 3Department of Essential
Medicines and Health Products, World Health Organization, Geneva, SwitzerlandSummary
Currently, access to treatment for HCV is limited, with treatment
rates lowest in the more resource-limited countries, including
those countries with the highest prevalence. The use of oral DAAs
has the potential to provide treatment at scale by offering
opportunities to simplify drug regimens, laboratory require-
ments, and service delivery models. Key desirable characteristics
of future HCV treatment regimens include high efﬁcacy, tolerabil-
ity, pan-genotype activity, short treatment duration, oral therapy,
affordability, and availability as ﬁxed-dose combination. Using
such a regimen, HCV treatment delivery could be greatly simpli-
ﬁed. Treatment could be initiated following conﬁrmation of the
presence of viraemia, with an initial assessment of the stage of
liver disease. A combination DAA therapy that is safe and effec-
tive across genotypes could remove the need for genotyping
and intermediary viral load assessments for response-guided
therapy and reduce the need for adverse event monitoring.
Simpler, safer, shorter therapy will also facilitate simpliﬁed
service delivery, including task shifting, decentralization, and
integration of treatment and care. The opportunity to scale up
HCV treatment using such delivery approaches will depend on
efforts needed to guarantee that the new DAAs are affordable
in low-income settings. This will require the engagement of all
stakeholders, ranging from the companies developing these
new treatments, WHO and other international organizations,
including procurement and funding mechanisms, governments
and civil society.
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In April 2014, the World Health Organization (WHO) released its
ﬁrst set of global guidelines for hepatitis C virus (HCV) treatment
[1]. These guidelines include recommendations for the use of
recently approved oral direct-acting antivirals (DAAs) that have
shown high treatment success rates with limited side effects
and shorter treatment duration compared to interferon-based
therapy.
Currently, access to treatment for HCV is limited, with only a
minority of the estimated 130–150 million people infected
world-wide receiving a diagnosis, and even fewer assessed for
eligibility and initiated on treatment. Treatment rates are lowest
in resource-limited countries [2], including those countries with
the highest prevalence [3]. Until now, key reasons for limited
treatment access have been the cost, complexity, limited effec-
tiveness of treatment, and lack of access to reliable and affordable
diagnostics. The standard treatment of pegylated-interferon and
ribavirin requires injections and thus is difﬁcult to administer,
is associated with common and sometimes severe adverse drug
reactions, and has limited treatment success that varies
according to genotype. These challenges, together with the long
treatment duration and high prices, have restricted treatment
to specialist centres, with patients selected according to their
chances of achieving treatment success, as determined by
genotyping and early virological response.
The use of oral DAAs has the potential to substantially
increase success rates for treatment-naïve patients, from around
50% with pegylated-interferon and ribavirin (with signiﬁcantly
lower rates for certain genotypes and among HIV co-infected
individuals) [4,5] to over 90% with sofosbuvir-based regimen
[6,7]. This, together with the improved safety and tolerability,
shorter treatment duration, and simpler administration
compared to the interferon-based therapy, opens up the prospect
of providing treatment at scale, including in resource-limited
settings.
The situation for HCV treatment today has been compared
with the situation for HIV treatment in the late 1990s, when com-
bination antiretroviral therapy was found to dramatically reduce
mortality among people living with HIV, but access to diagnostics
and treatment was extremely limited in resource-limited
settings where the vast majority of the 34 million people infected14 vol. 61 j S132–S138
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reside [8]. HIV and HCV share common routes of infection; both
diseases have a long period of asymptomatic infection before the
appearance of symptoms, and both lack an effective vaccine.
There are also important differences, notably the more important
contribution of sexual transmission in the case of HIV, and the
possibility of cure following antiviral therapy in the case of
HCV. Nevertheless, HCV and HIV have a number of important
overlapping challenges, and efforts to control HCV infection can
be informed by the experience of the global HIV response.
This article discusses the recent advances in HCV treatment
and reﬂects on the evolution of the public health response to
HIV/AIDS over the last decade to outline opportunities for
expanding access to HCV treatment provided by advances in
treatment (Table 1).
Key Points
• Direct acting antivirals with improved efficacy and 
tolerability, shorter treatment duration and simpler 
administration open up the potential to provide HCV 
treatment at scale, including in resource-limited 
settings
• Key desirable characteristics of HCV therapy include 
high efficacy, tolerability, pan-genotypic activity, short 
treatment duration, oral therapy, affordability and 
availability as fixed-dose combination
• Strategies to support access to treatment at scale 
include simplification of screening for treatment, 
treatment regimens, laboratory monitoring, and service 
delivery
• Efforts are needed to guarantee that the new DAAs are 
affordable in low- and middle-income settings Approaches to the simpliﬁcation of HCV treatment delivery
The ﬁrst set of WHO guidelines for antiretroviral therapy (ART)
for HIV/AIDS in resource-limited settings, released in 2002, were
presented as guidelines for a public health approach [9]. At the
time these guidelines were launched, there were over 20 drugs
available to treat HIV, and the established model of care was
developed in the USA and Europe where HIV was managed by a
team of medical specialists, using a range of diagnostic tests
and treatments tailored to individual needs and preferences.
Central to the public health approach for ART delivery was the
simpliﬁcation of treatment initiation, therapeutic options and
laboratory monitoring requirements, which in turn led to a
simpliﬁcation of service delivery. This approach allowed for a
greater role of patients in the self-management and care of HIV
[10]. At each step, parallels can be drawn with the potential
offered by DAAs to simplify HCV treatment delivery.
The availability of safe, simple, efﬁcacious and affordable
treatment for HIV has allowed delivery of treatment to over
10 million people within a decade. In a similar way, the new
DAAs offer the opportunities to simplify drug regimens, labora-
tory requirements, and service delivery models to scale up
treatment.Journal of Hepatology 2014Simpliﬁcation of screening for treatment
The last decade of antiretroviral therapy provision to people
living with HIV/AIDS in resource-limited settings has seen a
gradual shift towards expanded treatment eligibility as the
risk-beneﬁt proﬁle has evolved towards favouring earlier treat-
ment [11]. The latest WHO guidelines for antiretroviral therapy
provide recommendations for initiating treatment in certain
populations without any baseline laboratory testing beyond con-
ﬁrmation of HIV positive status (a so-called ‘‘test-and-treat’’
approach). Where this is not recommended, treatment initiation
is based on a simple clinical or immunological assessment,
without the need for baseline genotyping or viral load.
In well-resourced settings, a range of laboratory tests are
required prior to initiation of HCV treatment, including conﬁrma-
tion of antibody screening, followed by RNA PCR to conﬁrm the
presence of viraemia, assessment of liver disease severity (using
non-invasive tests or liver biopsy), viral load, HCV genotype
and subtype determination, and host genetics [12]. All of these
tests depend on a level of laboratory infrastructure that is poorly
accessible in resource-limited settings. HCV treatment scale-up
will need the expansion of screening, with easy access to
conﬁrmatory testing, or the development of a combined test
(e.g. antibody and antigen) [13] for a one-step diagnosis. The
improved safety proﬁle of the new DAAs and improved efﬁcacy
across genotypes allows for the possibility to greatly simplify
the approach to pre-treatment screening, possibly to the point
that, in the future, HCV treatment could be initiated following
conﬁrmation of infection and the presence of viraemia, with an
initial assessment of the stage of liver disease, without requiring
further baseline tests.
Simpliﬁcation of treatment regimens
For HIV there are currently 27 U.S. Food and Drug Administration
(FDA)-approved antiretrovirals (ARVs) that collectively target ﬁve
different points in the HIV life cycle. In order to scale up treat-
ment, efforts have been made to standardize the number of treat-
ment options recommended for use in resource-limited settings.
The WHO-recommended ﬁrst-line formulary for HIV therapy has
been reduced from ﬁve recommended options in 2002 to a single
preferred option in 2013 [9]; ﬁxed-dose combination therapy is
preferred as this facilitates drug supply management and has
been shown to be associated with improved adherence and
clinical outcomes compared to separate tablets [14].
As of September 2014, six drugs were approved by the FDA for
the treatment of HCV – standard interferon (IFN) or pegylated
interferon alpha (PegIFN), ribavirin (RBV), three protease inhibi-
tors (boceprevir, simeprevir, and telaprevir), and the nucleotide
analogue and polymerase inhibitor sofosbuvir. There is a robust
pipeline of new drugs for HCV treatment, with over 25 new
drugs and combinations in clinical development, including two
nucleotide polymerase inhibitors, six non-nucleoside polymerase
inhibitors, eight non-structural protein inhibitors, seven protease
inhibitors, one microRNA targeting compound, and several ﬁxed-
dose combinations (Table 2) [15]. While there has been a pressing
need for improved treatments, the availability of such an exten-
sive number of drugs also comes with challenges, including the
need to simplify prescribing, and ensuring availability at an
affordable price.vol. 61 j S132–S138 S133
Table 1. Key steps to facilitate scale-up access to DAAs in low- and middle-income settings.
Key steps for allowing delivery of HCV treatment at 
scale 
Potential approach
Simplified screening for treatment •
•
Combined test (e.g. antibody and antigen) for one-step diagnosis
Standardization of treatment regimens Definition of limited number of preferred regimens for resource-limited settings 
Key characteristics: 
- oral
- pan-genotypic
- interferon-free
- fixed-dose combination
Simplified laboratory monitoring • Definition of a minimal package of diagnostic and monitoring tests
Service delivery • Delegation of key tasks to lesser trained health staff
• Decentralization of care to lower level health facilities
Patient self-management • Promotion of patient-centred treatment literacy and adherence support 
Access to affordable medicines • Voluntary licensing
• Compulsory licensing
• Patent oppositions
• Increased price transparency
• Patent sharing arrangements
• Bulk procurement
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Journal of Hepatology Update: Hepatitis CCurrent HCV regimen choices (even with DAAs) vary, depend-
ing on cirrhosis, previous treatment and other considerations but
it is anticipated that improved efﬁcacy will allow for a single
combination regimen for the majority of patients. While the ideal
combination therapy remains to be established, key desirable
characteristics include high efﬁcacy, tolerability, pan-genotypic
activity, short treatment duration, oral therapy, affordability
and availability as ﬁxed-dose combination. In order to be able
to deliver treatment at scale in resource-limited settings it will
be important to focus on a limited number of regimens to
facilitate procurement and prescribing. Ideally, HCV treatment
should be formulated as an oral, pan-genotypic, interferon free,
ﬁxed-dose combination therapy.
There are an estimated 4–5 million people co-infected with
both diseases, with substantial regional variation [16]. The deci-
sion to initiate treatment for HCV in HIV-coinfected individuals
has until now been more complex than in those with HCV
monoinfection as response rates are lower, risk of potential
toxicities is higher and treatment is complicated by a high pill
burden, overlapping toxicities, and interactions between drugs
used for treating HCV and HIV. This, too, can be expected to
become simpler as regimens improve.Simpliﬁcation of laboratory monitoring
Over the last decade WHO’s recommendations for laboratory
monitoring of antiretroviral therapy have evolved, with the most
recent guidelines recommending HIV viral load as the preferred
way to monitor the response to treatment [17]. Currently, efforts
are underway to scale up access to viral load monitoring. Until
now, genotyping has played a very limited role, reﬂecting its lim-
ited availability, and has been reserved for the conﬁrmation of
treatment failure. With the increase in antiretroviral drug resis-
tance, and the gradual improvement in laboratory infrastructure,
genotyping may play a greater role in the future, but it is unlikely
that it will be required for all patients as a precondition to start-
ing treatment. With a careful sequencing of ﬁrst- and second-lineS134 Journal of Hepatology 2014drug regimens, the majority of patients will still be able to be ini-
tiated on treatment, and switched to an alternative regimen in
case of virological failure, without the need for genotyping.
The management of treatment for HCV using interferon-based
therapy requires intensive laboratory monitoring to assess treat-
ment efﬁcacy and monitor adverse events. Clinical chemistry, full
blood count, and HCV RNA are all measured at baseline with
repeated measures during the course of treatment. Guidelines
from the European Association for the Study of the Liver recom-
mend that HCV RNA levels should be assessed at baseline, week
4, end of treatment (week 12 or 24 depending on regimen), and
12 or 24 weeks after the end of therapy in order to assess sus-
tained virological response [18]. Following treatment initiation,
HCV RNA levels are used to guide decisions about continuation
of therapy. Current WHO guidelines for the treatment of people
with HCV infection acknowledge the need for access to appropri-
ate laboratory facilities in order to monitor the toxicity and
efﬁcacy of the treatment [1].
DAAs can provide opportunities to reduce laboratory mon-
itoring requirements. Until now, genotyping has been a
pre-condition for starting treatment, to determine the duration
of therapy, and the prospects of success. However, genotyping
capability is limited in many low and middle-income countries,
which in turn limits treatment. If a pan-genotypic DAA combina-
tion regimen, efﬁcacious against all genotypes, can be developed
and a single treatment duration established, this will remove the
need for genotyping.
In addition, a greater treatment efﬁcacy and tolerability
means that the number of tests could be reduced. Previous
monitoring algorithms have relied on a number of intermediary
viral load tests to ensure that treatment is only continued in
those patients who are likely to achieve a sustained virological
response. DAAs could allow for a reduction or elimination of
interim treatment efﬁcacy assessments, and could provide an
end to response-guided therapy.
Finally, requirements for adverse event monitoring can be
greatly reduced through the use of drugs with superior safety
proﬁles.vol. 61 j S132–S138
Table 2. The hepatitis C drug development pipeline.
Regimen, sponsor, status  Pan-genotypic Safe, effective in 
advanced liver 
disease
Acceptable 
tolerability (data 
may be limited); 
AEs in ≥10%:
Manageable 
drug-drug
interactions
Duration 
≤12 wk
QD Studied in
HIV/HCV
SVR 
≥90% 
3-D + RBV
(ABT-450/r + ABT-267 FDC, + ABT-
333)
NCT01685203
NCT01716585
NCT01833533
NCT01767116
Ritonavir-boosted protease inhibitor, 
NS5A inhibitor FDC, with non-
nucleoside polymerase inhibitor and 
RBV
AbbVie
Approval expected in 2014
No; 
G1 and G4
Yes
NCT01704755
Anemia
Asthenia
Diarrhea
Dry skin
Dyspnea
Fatigue
Headache
Irritability 
Insomnia
Nausea
Pruritus
Rash
Unclear Yes No Yes; trial 
underway
NCT01939197
Yes
Asunaprevir + BMS-791325 + 
daclatasvir ± RBV or sofosbuvir
NCT01979939
NCT02098616
NCT02175966
Protease inhibitor, non-nucleoside 
polymerase inhibitor, plus NS5A 
inhibitor; coformulation in development 
± RBV or sofosbuvir
BMS
Approval expected in 2015/2016
G1 Trial underway
NCT01973049
Abdominal pain
Asthenia
Diarrhea 
Headache 
Nausea
Unclear Yes No No; trial of 
asunaprevir and
daclatasvir  
underway
NCT02124044
Yes
Daclatasvir (+ sofosbuvir) 
NCT01359644
NS5A inhibitor plus nucleotide 
polymerase inhibitor 
BMS
Sofosbuvir is approved in the US and 
the EU; daclatasvir is approved in the 
EU; FDA approval anticipated in Q4 
2014
Yes; data in 
G1, 2, 3; 
phase III trials 
underway in all 
genotypes
NCT02032901
Yes; trial underway
NCT02032875
Fatigue 
Headache 
Nausea
Yes X
Duration 
currently 
under 
study in 
phase III 
trials
Yes Yes; trial 
underway
NCT02032888
Yes
Sofosbuvir/ledipasvir FDC 
NCT01701401
NCT01768286
NCT01851330
Nucleotide polymerase inhibitor, NS5A 
inhibitor
Gilead
Approval expected in 2014
Primarily G1 Yes 
NCT01965535
(from RBV-free 
arms only)
Asthenia 
Cough
Diarrhea, Fatigue
Headache 
Irritability
Insomnia
Nausea, Pruritus
Rash
Unclear Yes Yes Yes Yes
(continued on next page)
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Table 2. (continued)
Sofosbuvir/GS-5816 FDC
Nucleotide polymerase inhibitor, NS5A 
inhibitor
Gilead
Approval expected in 2015/2016
Yes
NCT02201940
NCT02201953
NCT01858766
NCT01858766
Trial underway; 
NCT02201901
Constipation 
Fatigue
Headache
Nausea 
Unclear Yes Yes No Yes
Sofosbuvir + RBV
NCT01497366
NCT01542788
NCT01441180
NCT01682720
Gilead
Approved
Yes Yes
NCT01687257
Anemia 
Arthralgia
Cough
Diarrhea 
Dizziness, Fatigue 
Headache
Insomnia, Irritability 
Nausea, Pruritus 
Rash
Upper respiratory 
tract infection 
Yes
NCT01565889
Only in 
G2;
24 
weeks 
for G1,3 
and 4
No Yes
NCT01667731
NCT01783678
NCT02220868
Only in 
G2
Sofosbuvir + PegIFN/RBV 
NCT01641640
Gilead; Roche/Merck; and 
generic producers
Approved
Yes Unclear Anemia, Cough 
Dizziness, Fatigue
Headache  
Insomnia
Myalgia
Nausea 
Neutropenia  
Pruritus
Rash
Yes Yes No Yes
NCT01565889
Yes
Sofosbuvir + simeprevir
NCT01466790
Nucleotide polymerase inhibitor; 
protease inhibitor 
Gilead/Janssen
Approved separately in 2013, off-label 
use
G1 X* (RBV-free arms 
only) 
Pruritus
Rash
Unclear Yes Yes No Yes
MK-5172 + MK-8742
NCT01717326
NCT02105467
Protease inhibitor and NS5A inhibitor; 
coformulation in development
Merck
Approval expected in 2015/2016 
Studies in
G4, 5 and 6 
planned; also 
being studied 
with sofosbuvir 
in G1, 2 and 3   
and RBV in G2
NCT02133131
NCT01932762
Yes
NCT02115321
NCT01717326
(RBV-free arms 
only) 
Asthenia
Fatigue 
Headache
Nausea 
Unclear Unclear Yes Yes
NCT02105662
NCT01717326
Yes
Regimen , sponsor, status  Pan-genotypic Safe, effective in 
advanced liver 
disease
Acceptable 
tolerability (data 
may be limited); 
AEs in ≥10%:
Manageable 
drug-drug
interactions
Duration 
≤12 wk
QD Studied in
HIV/HCV
SVR 
≥90% 
Relevant completed or ongoing trials are listed by clinical trial identiﬁers under populations studied, in bold. For further details see http://clinicaltrials.gov.
⁄Child–Pugh class A cirrhosis only.
FDC, ﬁxed-dose combination; IFN, interferon; RBV, ribavirin.
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Simpliﬁcation of service delivery
Throughout low and middle-income countries there is a critical
shortage of specialist medical and laboratory professionals [19].
In order to deliver treatment and care for people living with
HIV at scale, service delivery models needed to be simpliﬁed after
careful evaluation, such that the majority of routine care could be
delivered by nurses and other non-physician health workers.
Randomized trials in Uganda [20], South Africa [21,22], and
Kenya [23] have evaluated outcomes of HIV care delivered by
physicians and specialist compared to that delivered by nurses
and non-physician health workers. The results of these trials have
all found task-shifting to be safe, resulting in equivalent clinical
outcomes, and this approach is recommended by the World
Health Organization for the initiation and follow-up of treatment
[17]. In addition to increasing the number of health workers who
are able to manage patients task shifting also allows for the
decentralization of service delivery from hospitals, where doctors
are generally located, to health centres that are generally run by
non-physician providers [24]. The availability of treatment regi-
mens against HIV that were simple to prescribe, with minimal
pill burden, side-effects, and drug interactions, was central to
supporting the expansion of service delivery.
Experience to date in delivering HCV treatment has largely
rested with specialist physicians in hospital settings. Neverthe-
less, the limited availability of treatment even in high-income
countries has motivated programmes to pilot task shifting and
decentralization of treatment in order to improve access in
remote areas. In New Mexico, primary care providers were
trained and mentored in order to increase access to HCV therapy
for underserved populations; outcomes in terms of treatment
success and adverse event rates were comparable with care pro-
vided at a specialist HCV clinic [25]. In rural Canada, nurses were
trained to support the clinical management of HCV therapy with
physician oversight and achieved treatment outcomes compara-
ble to published trials [26]. A similar programme of nurse-led,
specialist-supported delivery of antiviral therapy was established
in three correctional centres in Australia, and this programme
likewise achieved outcomes consistent with those reported from
specialist clinics [27]. Notably, all these programmes used ther-
apy based on interferon or pegylated-interferon and ribavirin;
such approaches should be even more feasible using DAAs.
Finally, in settings of high HIV-HCV co-infection, integration
of HCV-related treatment services will be important as this
approach has been found to lead to improved patient outcomes
in other areas, including HIV and TB, maternal, new-born, and
child health services [28].Patient self-management
An important beneﬁt of having a simple, once-daily regimen with
minimal toxicity is that it facilitates treatment literacy among
patients, which promotes adherence and improves patient
outcomes for a range of chronic diseases [29]. Contrary to expec-
tations, adherence to antiretroviral therapy for HIV in resource-
limited settings has been found to be at least as good as that
reported in well-resourced settings [30], and clinical trials have
found that outcomes from self-administered therapy are equiva-
lent to those obtained through directly observed treatment [31].
Part of the explanation put forward for these results has been the
contribution of patient self-management (i.e. patients administerJournal of Hepatology 2014their own treatment without the need for direct physician
observation) and lay treatment supporters to help patients
adhere to treatment [32].Affordability of the new treatment regimes
HCV treatment is expensive, costing as much as US$84,000 in the
U.S. for a single 12-week course of sofosbuvir. Egypt, however
the country with the highest infection rates for HCV, has man-
aged to negotiate a price of US$900 per 12 weeks treatment of
sofosbuvir. Production costs for the new HCV DAAs are reported
to be comparable to those of HIV ART [33]; so in principle, similar
price reductions should be possible.
Treatment for HIV was initially prohibitively expensive. At
ﬁrst, triple antiretroviral therapy was priced beyond the reach
of resource-limited settings, but from 2001 more affordable gen-
eric versions became available as ﬁxed-dose combinations. This
allowed national programmes, supported by international
donors, to make treatment available at scale [34].
The most effective means to drive prices down to marginal
costs plus beneﬁt is generic competition. For HIV, political will
at a national and international level, initiated by pressure from
patient and civil society groups, led to increased funding, which
allowed for economies of scale. WHO standard treatment guide-
lines streamlined the drug market and concentrated demand on
recommended drugs. The creation of the UN/WHO prequaliﬁca-
tion programme that guaranteed the quality of ART allowed
international programmes to procure from prequaliﬁed cheaper
manufacturers from developing countries. This was possible as
India had used the WTO transitional periods and introduced pat-
ent protection for pharmaceutical products only in 2005. Thus
Indian companies could produce generic copies before patents
in other countries expired. Other factors include: (i) the use of
instruments, available under the WTO Agreement on Trade-
Related Aspects of Intellectual Property Rights, to access afford-
able medicines, including compulsory licenses and patent oppo-
sitions; (ii) increased price transparency through, for example,
the WHO Global Price Reporting Mechanism that reports pro-
curement prices of ARVs and thus, allows countries to compare
their performance in procurement; and (iii) the creation of the
Medicines Patent Pool in 2010, which led to an increasing num-
ber of license agreements, which in turn has allowed for early
generic competition and (iv) price reductions by pharmaceutical
companies. Many of these factors can in principle be replicated
for the new DAAs. One difference is that with the new product
patent regime in India, there is a need for a broader diversity of
sources of generic products. Another challenge is the different
distribution of the disease burden which, unlike for HIV is less
concentrated in sub-Saharan Africa and lower income countries.
Conclusions
Recent years have seen a growing commitment to improving
access to treatment and care for people infected with HCV. Two
World Health Assembly Resolutions, passed in 2010 [35] and
2014 [36] and adopted unanimously, demonstrate high-level
political commitment from national governments and UN agen-
cies towards improving the response against HCV.
The arrival of new oral therapies with high rates of treatment
success has been rightly met with enthusiasm, and it isvol. 61 j S132–S138 S137
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conceivable that a pan-genotypic, highly effective, easily admin-
istered medication which requires little or no monitoring for
adverse events could be developed within the next few years.
The potential impact of such a treatment will extend well beyond
improved cure rates as shorter, simpler, safer treatment allows
for the possibility of delivering antiviral therapy at scale. Task
shifting, decentralization, and patient engagement have been
central to expanding access to treatment for HIV and have
already shown promise in expanding access to HCV treatment
without compromising on patient care.
As more drugs progress through clinical development, the
need for simpliﬁed regimens should be prioritized. Pan-genotypic
regimens with minimal side effects that can be combined as
ﬁxed-dose combinations, and that are available at an affordable
price, will have the greatest potential to simplify treatment and
expand access. Efforts will be needed to guarantee that the new
DAAs are affordable in low-income settings. This will require
the engagement of all stakeholders, ranging from the companies
developing these new treatments, WHO and other international
organizations, including procurement and funding mechanisms,
governments and civil society.Conﬂict of interest
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